NEW YORK, Dec. 01, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Elanco Animal Health Incorporated (NYSE: ELAN) between November 7, 2023 and June 26, 2024, both dates inclusive (the “Class Period”), of the important December 6, 2024 lead plaintiff deadline. SO WHAT: If you purchased Elanco securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee a ...

Core Viewpoint - A federal lawsuit has been filed against Elanco Animal Health Inc. and certain executives for allegedly making false and misleading statements regarding the safety and market prospects of Zenrelia, an oral Janus kinase inhibitor, during the class period from November 7, 2023, to June 26, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Elanco downplayed potential safety risks associated with Zenrelia while overstating its chances for a quick U.S. market launch [2]. - The controversy intensified on June 26, 2024, when Elanco announced that Zenrelia's label would include a boxed warning due to safety issues identified in trials with unvaccinated dogs, which is expected to significantly impede product adoption [3]. Group 2: Market Impact - Following the announcement of the boxed warning, Elanco's stock fell by over 20% [4]. - During the Q2 earnings call on August 4, 2024, CEO Jeffrey N. Simmons acknowledged that the warning would "slow the initial product adoption curve" and projected a 25% reduction in treatment days due to limitations related to vaccine usage [4]. Group 3: Investigation and Legal Actions - Law firm Hagens Berman is investigating the allegations to determine the accuracy and truthfulness of Elanco's representations regarding Zenrelia's safety [5]. - The firm is encouraging investors who have suffered substantial losses to come forward and submit their claims [6].

NEW YORK, Nov. 30, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

NEW YORK, Nov. 28, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

SAN DIEGO, Nov. 25, 2024 /PRNewswire/ -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Elanco Animal Health Incorporated (NYSE: ELAN) securities between November 7, 2023 and June 26, 2024. Elanco is an animal health company that develops, manufactures, and markets products for pets and farm animals.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: R ...

PHILADELPHIA, Nov. 25, 2024 (GLOBE NEWSWIRE) --  Berger Montague PC advises investors that a securities class action lawsuit has been filed against Elanco Animal Health Inc. (“Elanco” or the “Company”) (NYSE: ELAN) on behalf of purchasers of Elanco securities between November 7, 2023 and June 26, 2024, inclusive (the “Class Period”). Investor Deadline: Investors who purchased or acquired ELANCO securities during the Class Period may, no later than DECEMBER 6, 2024, seek to be appointed as a lead plaintiff r ...

GREENFIELD, Ind, Nov. 25, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that management will participate in upcoming investor conferences.On Tuesday, December 3, Todd Young, executive vice president and CFO, will participate in a fireside chat at the Evercore ISI 7th Annual HealthCONx at 11:15 a.m. ET.On Thursday, December 5, Todd Young will participate in the Piper Sandler 36th Annual Healthcare Conference at 1:30 p.m. ET.Live audio webcasts will be available in the "E ...

NEW YORK, Nov. 24, 2024 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Elanco Animal Health Incorporated (NYSE: ELAN) between November 7, 2023 and June 26, 2024, both dates inclusive (the "Class Period"), of the important December 6, 2024 lead plaintiff deadline.So what: If you purchased Elanco securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangem ...

NEW YORK, Nov. 24, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...